Tiziana Life Sciences Ltd (NASDAQ:TLSA), a biotechnology firm developing immunomodulation therapies, including intranasal foralumab, said its executive chairman and founder, Gabriele Cerrone, purchased 97,687 common shares.
The acquisition brings his total holding to 43,374,830 shares, representing 36.08% of Tiziana’s issued share capital.